Cargando…

Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi

There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi. METHODS: Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasonkanji, Edwards, Kimani, Stephen, Skiver, Brent, Ellis, Grace, Seguin, Ryan, Kaimila, Bongani, Tomoka, Tamiwe, Mulenga, Maurice, Montgomery, Nathan, Fedoriw, Yuri, Gopal, Satish, Westmorland, Katherine D., Painschab, Matthew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276115/
https://www.ncbi.nlm.nih.gov/pubmed/35772043
http://dx.doi.org/10.1200/GO.21.00388
_version_ 1784745644976504832
author Kasonkanji, Edwards
Kimani, Stephen
Skiver, Brent
Ellis, Grace
Seguin, Ryan
Kaimila, Bongani
Tomoka, Tamiwe
Mulenga, Maurice
Montgomery, Nathan
Fedoriw, Yuri
Gopal, Satish
Westmorland, Katherine D.
Painschab, Matthew S.
author_facet Kasonkanji, Edwards
Kimani, Stephen
Skiver, Brent
Ellis, Grace
Seguin, Ryan
Kaimila, Bongani
Tomoka, Tamiwe
Mulenga, Maurice
Montgomery, Nathan
Fedoriw, Yuri
Gopal, Satish
Westmorland, Katherine D.
Painschab, Matthew S.
author_sort Kasonkanji, Edwards
collection PubMed
description There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi. METHODS: Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, were enrolled from 2013 to 2019; follow-up was censored on December 2020. ALL diagnosis was confirmed on-site using immunohistochemistry and telepathology consultation involving pathologists in Malawi and the United States. All but four patients were treated with a modified pediatric-inspired regimen (Cancer and Leukemia Group B 10403 protocol). Key modifications included omission of asparaginase and no dose escalation for methotrexate. RESULTS: Of 19 participants, the median age was 22 (range 15-36) years. Of the 15 patients who initiated treatment, 11 (73%) achieved remission after induction, one (7%) died during induction, two (13%) had refractory disease, and one (7%) absconded. No patients were lost to follow-up. Eventually, 10 of 11 patients (91%) with confirmed remission relapsed. The median duration of first remission was 10 (range 3-22) months. Twelve of 15 treated patients (80%) had died at the time of censoring. Among treated patients, the 12- and 24-month overall survival was 50% (95% CI, 23 to 72) and 17% (95% CI, 3 to 42), respectively. CNS involvement was associated with worse survival. CONCLUSION: It is possible to treat adolescents and young adults with ALL in low-resource settings using a low-cost, pediatric-inspired regimen; however, outcomes are poor. Both cost and limitations in supportive care infrastructure limit intensive cytotoxic approaches such as asparaginase. Patient-reported outcomes are needed to understand the quality of life and cost-effectiveness. Critically, innovative, leap-frog therapies, such as monoclonal or bispecific antibodies, and feasible economic models for resource-limited settings are urgently needed.
format Online
Article
Text
id pubmed-9276115
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-92761152022-07-13 Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi Kasonkanji, Edwards Kimani, Stephen Skiver, Brent Ellis, Grace Seguin, Ryan Kaimila, Bongani Tomoka, Tamiwe Mulenga, Maurice Montgomery, Nathan Fedoriw, Yuri Gopal, Satish Westmorland, Katherine D. Painschab, Matthew S. JCO Glob Oncol ORIGINAL REPORTS There are limited data on treatment and outcomes for acute lymphoblastic leukemia (ALL) among adolescents and young adults in sub-Saharan Africa. We describe a prospective observational cohort in Malawi. METHODS: Patients age 15-39 years with newly diagnosed ALL at Kamuzu Central Hospital, Malawi, were enrolled from 2013 to 2019; follow-up was censored on December 2020. ALL diagnosis was confirmed on-site using immunohistochemistry and telepathology consultation involving pathologists in Malawi and the United States. All but four patients were treated with a modified pediatric-inspired regimen (Cancer and Leukemia Group B 10403 protocol). Key modifications included omission of asparaginase and no dose escalation for methotrexate. RESULTS: Of 19 participants, the median age was 22 (range 15-36) years. Of the 15 patients who initiated treatment, 11 (73%) achieved remission after induction, one (7%) died during induction, two (13%) had refractory disease, and one (7%) absconded. No patients were lost to follow-up. Eventually, 10 of 11 patients (91%) with confirmed remission relapsed. The median duration of first remission was 10 (range 3-22) months. Twelve of 15 treated patients (80%) had died at the time of censoring. Among treated patients, the 12- and 24-month overall survival was 50% (95% CI, 23 to 72) and 17% (95% CI, 3 to 42), respectively. CNS involvement was associated with worse survival. CONCLUSION: It is possible to treat adolescents and young adults with ALL in low-resource settings using a low-cost, pediatric-inspired regimen; however, outcomes are poor. Both cost and limitations in supportive care infrastructure limit intensive cytotoxic approaches such as asparaginase. Patient-reported outcomes are needed to understand the quality of life and cost-effectiveness. Critically, innovative, leap-frog therapies, such as monoclonal or bispecific antibodies, and feasible economic models for resource-limited settings are urgently needed. Wolters Kluwer Health 2022-06-30 /pmc/articles/PMC9276115/ /pubmed/35772043 http://dx.doi.org/10.1200/GO.21.00388 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle ORIGINAL REPORTS
Kasonkanji, Edwards
Kimani, Stephen
Skiver, Brent
Ellis, Grace
Seguin, Ryan
Kaimila, Bongani
Tomoka, Tamiwe
Mulenga, Maurice
Montgomery, Nathan
Fedoriw, Yuri
Gopal, Satish
Westmorland, Katherine D.
Painschab, Matthew S.
Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
title Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
title_full Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
title_fullStr Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
title_full_unstemmed Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
title_short Clinical Characteristics and Outcomes of Acute Lymphoblastic Leukemia in Adolescents and Young Adults in Malawi
title_sort clinical characteristics and outcomes of acute lymphoblastic leukemia in adolescents and young adults in malawi
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276115/
https://www.ncbi.nlm.nih.gov/pubmed/35772043
http://dx.doi.org/10.1200/GO.21.00388
work_keys_str_mv AT kasonkanjiedwards clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT kimanistephen clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT skiverbrent clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT ellisgrace clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT seguinryan clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT kaimilabongani clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT tomokatamiwe clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT mulengamaurice clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT montgomerynathan clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT fedoriwyuri clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT gopalsatish clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT westmorlandkatherined clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi
AT painschabmatthews clinicalcharacteristicsandoutcomesofacutelymphoblasticleukemiainadolescentsandyoungadultsinmalawi